SINOGRAFIN Drug Patent Profile
✉ Email this page to a colleague
When do Sinografin patents expire, and what generic alternatives are available?
Sinografin is a drug marketed by Bracco and is included in one NDA.
The generic ingredient in SINOGRAFIN is diatrizoate meglumine; iodipamide meglumine. There are eleven drug master file entries for this compound. Additional details are available on the diatrizoate meglumine; iodipamide meglumine profile page.
Summary for SINOGRAFIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 32 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SINOGRAFIN at DailyMed |
US Patents and Regulatory Information for SINOGRAFIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bracco | SINOGRAFIN | diatrizoate meglumine; iodipamide meglumine | SOLUTION;INTRAUTERINE | 011324-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |